MN 553 Unit 3 Assignment: Gastrointestinal System Drug

Part 1

Choose a drug that is used for the GI system. Write a legal prescription for the drug for a fictitious patient. You are the provider. Be sure your prescription includes all legally correct patient information, provider information, medication information as well as any special instructions to the pharmacist. Your writing Assignment should include all the legal elements of a prescription.

Part 2

Write a 250-300 word paper to describe the pharmacokinetics and pharmacodynamics of the drug as well as specific patient education about the chosen drug. Reference your work using correct APA formatting. Utilize correct professional writing including grammar, punctuation, and mechanics.Directions

ORDER A CUSTOMIZED, PLAGIARISM-FREE PAPER HERE

We can write this assignment for you and pay after Delivery. Our Top -rated medical writers will comprehensively review instructions , synthesis external evidence sources(Scholarly) and customize a quality assignment for you. We will also attach a copy of plagiarism report alongside an AI report. Feel free to chat Us

 A SAMPLE SAMPLE BY OUR TOP WRITER

Unit 3 Assignment: Gastrointestinal System Drug

Part 1: A Legal Prescription for Omeprazole

Institution: IU Health University Hospital…………….

Address: …. 550 University Blvd, Indianapolis, IN 46202, United States……..

Patient Name……………

D.O.B…….14/07/1963…………

Age……60…………….

Address……….  IN ……………………………………………………………………..

Date: …05/02/2024……………………..

RX: PRILOSEC (Omeprazole) 20 mg PO daily for four weeks

Quantity: 28 delayed-release capsules

Refills: biweekly

Special instructions to pharmacists:

• Dispense as written (DAW)
• Monitor for difficile-associated diarrhea and hypomagnesia when taken for a long time.
• Review the medication after four weeks

Prescriber Name…………….

Address: ………………

DEA Number: ……..  Signature ……………

Part 2: Drug Pharmacokinetics, Pharmacodynamics, and Patient Education

Pharmacokinetics

Omeprazole is absorbed upon leaving the stomach by its enteric-coated granules. The drug has a rapid absorption rate and about 30% to 40% absolute bioavailability. The estimated time of the drug’s optimal plasma concentration is about 0.5 to 3.5 hours. The peak plasma concentrations of Omeprazole are primarily consistent with the drug doses of up to 40 mg. After its absorption, Omeprazole’s distribution entails a protein binding potential of about 95% (Food and Drug Administration, 2012). The liver metabolizes omeprazole by the cytochrome P450 system which comprises other enzymes, including CYP2C19, CYP2C9, and CYP3A4 (Jana et al., 2018). These enzymes produce plasma metabolites like hydroxyomeprazole and sulphone. About 77% of omeprazole metabolites are eliminated in urine while the remaining metabolites are eliminated in feces (Food and Administration, 2012). The estimated omeprazole plasma half-life is 0.5 to 1 hour.

Pharmacodynamics

As a proton pump inhibitor (PPI), omeprazole inhibits the parietal cell H+/K+ ATP pump. According to the US Food and Drug Administration (2012), the drug’s ability to bind to the parietal H+/K+ cells produces the antisecretory effect with occurs within one hour after its oral administration. Omeprazole’s antisecretory effect is useful in blinding the final step of gastric acid production and the subsequent treatment of duodenal and gastric ulcer and gastroesophageal reflux disease (GERD) in children and adults (Food and Drug Administration, 2012).

Patient Education

Pharmacists must provide adequate information to patients regarding appropriate omeprazole administration. According to Shah and Gossman (2023), omeprazole may predispose patients to side effects like regurgitation, diarrhea, flatulence, abdominal pain, and rash. Also, the drug may increase individual susceptibility to Clostridioides difficile (C. diff)-associated diarrhea (Shah & Gossman, 2023). Therefore, pharmacists should educate patients on the importance of avoiding concomitant omeprazole use with rifampin and amoxicillin. Further, patients should take omeprazole before eating and should not crash capsules since the drug has delayed-release capsules (Food and Drug Administration, 2012)

References

Food and Drug Administration. (2012). PRILOSEC (omeprazole) label (pp. 1–45). https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf

Jana, K., Bandyopadhyay, T., & Ganguly, B. (2018). Stereoselective metabolism of omeprazole by cytochrome P450 2C19 and 3A4: Mechanistic insights from DFT study. The Journal of Physical Chemistry B, 122(22), 5765–5775. https://doi.org/10.1021/acs.jpcb.8b01179

Shah, N., & Srivastava, P. (2023). Omeprazole. StatPearls Publishi